Jay S. Skyler, M.D., is a Professor of Medicine, Pediatrics, and Psychology and Director of the Division of Endocrinology, Diabetes and Metabolism at the University of Miami. Dr. Skyler is also Associate Director for Academic Programs at the Diabetes Research Institute. He is the Program Director of the University of Miami General Clinical Research Center. He was Study Chairman for the nationwide multicenter Diabetes Prevention Trial for Type 1 diabetes (DPT-1) and now serves as Study Chairman of its successor, the NIH-sponsored Type 1 Diabetes TrialNet, a nationwide network conducting clinical trials to interdict Type 1 diabetes. He has served the American Diabetes Association in many capacities, as well as several other diabetes organizations.

Bernard Zinman M.D., CM, FRCPC, FACP, is a Professor of Medicine at the University of Toronto, Canada and Senior Scientist at the Samuel Lunenfeld Research Institute, Mount Sinai Hospital. Dr. Zinman is Director of the Leadership Sinai Center for Diabetes and holds the Sam and Judy Pencer Family Chair in Diabetes Research at Mount Sinai Hospital and the University of Toronto. He was Director of the Banting and Best Diabetes Centre (1993-2000) and is now involved with diabetes care and research at both national and international levels. He is the Principal Investigator of the University of Toronto Centre for the DCCT/EDIC (Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications) study.

Julio Rosenstock, M.D., is the director of the Dallas Diabetes and Endocrine Center at Medical City, an endocrine practice and clinical research facility. He is also a clinical professor of medicine at the University of Texas Southwestern Medical Center at Dallas. He is board-certified in internal medicine, endocrinology and metabolism, member of numerous professional societies and serves as the representative of The Endocrine Society to NDEP (National Diabetes Education Program sponsored by NIH and CDC).
His clinical and research activities have focused on intensive diabetes management strategies exploring novel therapies to improve glycemic control to prevent and retard diabetic complications. Dr Rosenstock’s main interest has been early insulin intervention with combination strategies to reach glycemic targets in type 2 diabetes. He serves on the editorial board of Practical Diabetology and Cardiovascular Diabetology and is an active reviewer for several journals.

Steven E. Kahn, MB, ChB Metabolism, is a Professor of Medicine in the Division of Metabolism, Endocrinology and Nutrition at the University of Washington. Dr. Kahn has served on the editorial boards for Diabetes Care and the Journal of Clinical Endocrinology & Metabolism. He is a member of the board of directors of the American Diabetes Association (ADA) and has served as Chair of the Scientific and Medical Meetings Oversight Committee of the ADA. He is also a member of The Endocrine Society and the European Association for the Study of Diabetes. His current research interests include, but are not limited to, the assessment of islet function and insulin action in states of normal and abnormal carbohydrate metabolism and the role of fat distribution on metabolic variables associated with diabetes and cardiovascular disease.

Robert A. Gelfand M.D. is an Associate Professor of Clinical Medicine at Yale University. Dr. Gelfand practices Hematology, Internal Medicine, and Oncology in Connecticut and New York City. He is a Diplomate of the National Board of Medical Examiners, American Board of Internal Medicine, Subspecialty of Endocrinology and Metabolism. In addition, Dr. Gelfand is a member of the American Diabetes Association and American College of Physicians.